Fibrosis & Cirrhosis
  • Featured content
    Led by Norah Terrault, MD, MPH, a panel of experts including Gregory Dore, MBBS, PhD, FRACP, MPH; Graham R. Foster, FRCP, PhD; and Ira M. Jacobson, MD, provides an overview of the current state of HCV therapy, emphasizing the unprecedented levels of efficacy and simplicity in curing individual patients, and discusses important strategies for eliminating HCV infection across communities and ultimately throughout the world.
  • Featured content
    Listen to this downloadable audio from a live Webinar in which an expert faculty member discusses the clinical impact of new data reported at the Barcelona meeting.
    Date Posted: 6/1/2016
  • Featured content
    In this Interactive Case Challenge, Paul Y. Kwo, MD, explores important considerations when selecting all-oral HCV therapy for patients with cirrhosis.
  • Featured content
    In my practice, it is the patient with cirrhosis and genotype 3 HCV infection who causes me to pause and carefully consider the patient’s treatment options.
    Date Posted: 2/25/2016
  • Featured content
    While evaluating outcomes for individual educational activities is standard, much less work has been done analyzing CME outcomes across activities. Accordingly, we sought to evaluate learner performance on a cancer immunotherapy outcomes measure repeated in several different activities. Our findings suggest a clear and ongoing lack of basic knowledge regarding cancer immunotherapy principles that are increasing important for patient care. Bringing education on immunotherapy to clinicians via multiple formats (eg, symposium, live meeting series, online, on-demand activities) will facilitate greater and more effective use of these agents and, thereby, improve outcomes for patients.
    Date Posted: 2/2/2016
  • 1
  • 2
  • 3
  • 4
  • 5

Latest Content

10 of 57 Shown
10 of 57 Shown
Show 10 More